Subventions financées

Brain-Heart conditions such as cognitive impairment (trouble remembering and learning) or heart failure (heart muscle unable to pump enough blood) are becoming more common as we age.

In general, women take part in research less than men.

Alzheimer’s disease is a leading cause of dementia and cognitive decline.

The Canadian Platform for Trials in Non-Invasive Brain Stimulation (CanStim) is national research platform whose goal is to create a network of sites across Canada for clinical trials that can develop and test the use of different types of non-invasive brain stimulation as an additional therapy option for people with stroke to help them better recover their ability to move their hands and arms after a stroke.

Strokes often cause brain damage that can severely affect motor function, particularly fine movements of the hands and digits.

Spinal cord injury (SCI) leads to dramatic alterations in physical and mental well-being.

The development of approaches to aid early detection of the transition from healthy aging to mild cognitive impairment and Alzheimer’s disease (AD) is critically important for developing targeted strategies to halt or slow disease progression.

The early and severe loss of serotonin neurons along with the neuroprotective effects of SSRIs in Alzheimer’s Disease (AD) strongly implicates the serotonin system in disease pathology.

Our project proposes the development and first-step validation of a new, noninvasive mapping procedure of proteinopathy in asymptomatic older adults.

Many people with dementia (PwD) live in nursing homes, which often suffer from a lack of skilled staff to support and monitor the safety of residents.